Showing 1-9 of 9 results for "".
Women in Dermatology: Iris Rubin, MD
https://practicaldermatology.com/topics/practice-management/women-in-dermatology-iris-rubin-md/23589/- Mark Rubin, MDhttps://practicaldermatology.com/profiles/mark-rubin-md/LAab69/
- Iris Rubin, MDhttps://practicaldermatology.com/profiles/iris-rubin-md/LzA3qe/
Effective Patient Consultations: Keys to Success
https://practicaldermatology.com/topics/practice-management/effective-patient-consultations-keys-to-success/20122/So much depends on the patient consultation, and its key that all members of the practice staff are attentive to the needs of the patient and the practice. Amy Lewis, MD and Mark Rubin, MD weigh in on strategies for effective patient interactions.- The Skin Cancer Foundation Raises $625,000 For Skin Cancer Education Programs at Annual Galahttps://practicaldermatology.com/news/the-skin-cancer-foundation-raises-625000-for-skin-cancer-education-programs-at-annual-gala/2461200/The Skin Cancer Foundation Champions for Change Gala raised $625,000 in support of the organization’s educational campaigns, community programs and research initiatives. More than 300 guests attended the event, including Skin Cancer Foundation donors, industry and physician allies, celebrity supp…
- Fat Grafting Shows Promise for Cancer Patients with Radiation-induced Skin Injuryhttps://practicaldermatology.com/news/fat-grafting-shows-promise-for-cancer-patients-with-radiation-induced-skin-injury/2460730/As cancer survival rates improve, more people are living with the aftereffects of cancer treatment including chronic radiation-induced skin injury. Fat grafting procedures may unleash the healing and regenerative power of the body's natural adipose stem cells (ASCs). "Preliminary evidence suggests…
- A Pivotal Phase III Gevokizumab Study is Initiated in Patients With Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20141104-a_pivotal_phase_3_gevokizumab_study_is_initiated_in_patients_with_pyoderma_gangrenosum/2459074/The Phase III gevokizumab study in patients with active pyoderma gangrenosum, a rare neutrophilic dermatosis of expanding necrotic skin ulcers, is open for patient enrollment. The objective of the study is to assess the efficacy and safety of gevokizumab in treating the active ulcers caused by th…
- XOMA Finalizes Gevokizmab Phase III Clinical Program in Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140428-xoma_finalizes_gevokizmab_phase_3_clinical_program_in_pyoderma__gangrenosum/2459254/Xoma Corporation finalized the plans for gevokizumab Phase III Program in Pyoderma Gangrenosum (PG). The Phase III Study will include two double-blind placebo-controlled clinical studies with 60 patients who have active PG. Paul Rubin, Senior Vice President, Research and Development and Chief…
- Asclera's "Stand and Deliver" to Recognize Inspirational Womenhttps://practicaldermatology.com/news/20121101-ascleras_stand_and_deliver_to_recognize_inspirational_women/2459686/Nominations are being accepted through December 31, 2012 for the Stand and Deliver program sponsored by Merz Aesthetics, exclusive distributor of Asclera® (polidocanol) injection in the US. Stand and Deliver launched in 2011 to celebrate inspirational women making positive contributions to their…